Studies on CJC-1295, a long-acting GHRH analog, in growth hormone axis and body-composition research contexts.
Also called CJC-1295, CJC1295, growth hormone releasing hormone analog
Sources: 12 new papers · 5 key papers · updated Oct 20, 2026
Unverified · drafted by AI from the sources cited below
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH).1
Detection of CJC‐1295 in Equine Plasma by ELISA
Drug Testing and Analysis — Timms M — Oct 2026
Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review
Sexual Medicine Reviews — Vasylieva V — Sep 2026
From Mewing to Peptides: Looksmaxxing as an Emerging Pediatric Concern
PEDIATRICS — Mekhail J — Aug 2026
Peptide Supplements and Their Therapeutic Applications in Sports Medicine
The American Journal of Sports Medicine — Tewari K — Aug 2026
Regenerative Medicine in Orthopedics: Evaluating PRP, MSC Therapies, BPC-157, TB-4/TB-500, CJC-1295, Retatrutide, and Osteostatin as Complements to Conventional Care: A Narrative Review
Tebben N — Aug 2026
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Frontiers in Endocrinology — Dominikowski A — Jun 2026
Research Peptides for Sale: Quality Standards for BPC-157, TB-500, Sermorelin and Epitalon Procurement
Research E — May 2026
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications
JBJS Reviews — Meza A — May 2026
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Frontiers in Aging — Mavrych V — Apr 2026
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
The Journal of Sports Medicine and Physical Fitness — COUTINHO L — Mar 2026
Advances in the detection of growth hormone releasing hormone synthetic analogs
Drug Testing and Analysis — Memdouh S
19 citations · 2021 · among the most cited on CJC-1295
Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice
Scientific Reports — Recinella L
17 citations · 2021 · among the most cited on CJC-1295
The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders
Reviews in Endocrine and Metabolic Disorders — Schally A
14 citations · 2024 · among the most cited on CJC-1295
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
The American Journal of Sports Medicine — Mayfield C
12 citations · 2026 · among the most cited on CJC-1295
HIV-associated dyslipidemia: pathogenesis and its management
Chinese Medical Journal — Wan Z
11 citations · 2023 · among the most cited on CJC-1295
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.
Most-cited researchers publishing on CJC-1295.
